Bioporto CEO despite growing deficit: ”A fantastic six months”
Bioporto’s sales of antibodies and the kidney test NGAL for research use have grown rapidly in 2017. Despite this, the company is forced to downgrade its financial expectations, now expecting a larger deficit for the year. But there is a perfectly good reason for that, explains the CEO.
BY MIKKEL AABENHUS HEMMINGSEN
“This half year is the best I have experienced in Bioporto and progress is being made on all fronts.”
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
BioPorto has finished new protocol for FDA submission
For abonnenter
BioPorto signs US licensing deal
For abonnenter
